Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. CRN00808, Co.'s main product candidate, establishes a class of oral selective nonpeptide somatostatin receptor type 2 (sst2) biased agonists designed for the treatment of acromegaly. CRN0194 is an oral nonpeptide sst2 biased agonist for the treatment of neuroendocrine tumors that originate from neuroendocrine cells commonly found in the gut, lung or pancreas. Co. develops a class of oral selective nonpeptide somatostatin type 5 receptor agonists designed to treat congenital hyperinsulinism. The CRNX stock yearly return is shown above.
The yearly return on the CRNX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CRNX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|